RT Journal Article
SR Electronic
T1 Relative burdens of the COVID-19, malaria, tuberculosis, and HIV/AIDS epidemics in sub-Saharan Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.27.21254483
DO 10.1101/2021.03.27.21254483
A1 Bell, David
A1 Hansen, Kristian Schultz
YR 2021
UL http://medrxiv.org/content/early/2021/09/10/2021.03.27.21254483.abstract
AB COVID-19 has had considerable global impact, but in sub-Saharan Africa is one of several infectious disease priorities. Prioritization is normally guided by disease burden, but the highly age-dependent nature of COVID-19 and other infectious diseases makes comparisons challenging unless considered through metrics that incorporate life years lost and time lived in adverse health. We therefore compared 2020 mortality and Disability-Adjusted Life Years lost (DALYs lost) estimates for malaria, tuberculosis, and HIV/AIDS in sub-Saharan African populations with 12+ months of COVID-19 burden (up to end March 2021), applying known age-related mortality to United Nations estimates of age structure. We further compared exacerbations of disease burden predicted from the COVID-19 public health response. Data was derived from public sources, predicted exacerbations derived from those published by international agencies. For sub-Saharan African populations north of South Africa, recorded COVID-19 DALYs lost in 2020 was 3.7%, 2.3%, and 2.4% of those estimated for tuberculosis, HIV/AIDS and malaria respectively. Predicted exacerbations of these comparator diseases were greater than the estimated COVID-19 burden. Including South Africa and Lesotho, COVID-19 DALYs lost were <12% of those for comparator diseases and dominated by them in all age groups below 65 years. The analysis suggests a relatively low impact from COVID-19. While all four epidemics continue, tuberculosis, HIV/AIDS, and malaria remain far greater health priorities based on disease burden. Resource diversion to COVID-19 therefore runs a high risk of increasing the overall disease burden and causing net harm, further increasing global inequities in health and life expectancy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding source: None Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A. Public data only used.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is in the public domain, and calculations are freely available from the authors.Africa CDCAfrica Centres for Disease Control and PreventionAIDSAcquired Immune Deficiency SyndromeDALYsDisability-Adjusted Life YearsHIVHuman Immunodeficiency VirusSARS-CoV-2Severe Acute Respiratory Syndrome Corona Virus -2WHOWorld Health Organization